Response to : towards the rational utilization of SARS-CoV-2 serological tests in clinical practice
| Errataetall: |
CommentOn: Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. - PMID 32301749 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 59(2021), 6 vom: 26. Mai, Seite e227-e229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brown, Samuel D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 04.05.2021 Date Revised 27.05.2021 published: Electronic-Print CommentOn: Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. - PMID 32301749 Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2020-1762 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321150317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321150317 | ||
| 003 | DE-627 | ||
| 005 | 20231225175211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2020-1762 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321150317 | ||
| 035 | |a (NLM)33554513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brown, Samuel D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to |b towards the rational utilization of SARS-CoV-2 serological tests in clinical practice |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2021 | ||
| 500 | |a Date Revised 27.05.2021 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentOn: Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. - PMID 32301749 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Roche Elecsys | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a non-linearity | |
| 650 | 4 | |a serology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Ottaway, Kate A |e verfasserin |4 aut | |
| 700 | 1 | |a Weaving, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Shipman, Kate E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 59(2021), 6 vom: 26. Mai, Seite e227-e229 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2021 |g number:6 |g day:26 |g month:05 |g pages:e227-e229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2020-1762 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2021 |e 6 |b 26 |c 05 |h e227-e229 | ||